Lithium Orotate & NDGA: The Two Compounds Bryan Johnson Added to Blueprint in 2026

Why These Two Compounds Matter#

In early 2026, Bryan Johnson — the entrepreneur who has spent more on personal biomarker tracking than almost anyone alive — made the most significant revision to his Blueprint protocol since it launched. He dropped rapamycin entirely after concluding the immunosuppression tradeoff wasn't justified by his own bloodwork, cut his NMN/NR cycle from daily to six days a week, and added two new compounds focused specifically on brain protection: NDGA and microdose lithium orotate.

Johnson's protocol changes get attention not because he's a medical authority — he isn't — but because his "experiment of one" is the most extensively measured longevity protocol in existence, with monthly biomarker panels, continuous glucose monitoring, and quarterly full-body imaging providing a feedback loop most self-experimenters never have. When he changes something, it's worth understanding why — and separating the signal from the hype.

---

NDGA: Mouse-Study Gold Standard, Human Data Void#

What It Is#

NDGA (nordihydroguaiaretic acid) is a polyphenol extracted from the creosote bush (Larrea tridentata), a desert shrub used in traditional medicine across the American Southwest for centuries.

The Evidence That Matters#

NDGA's credibility in longevity circles comes from one source: the NIA Interventions Testing Program (ITP). The ITP is widely considered the gold standard for testing longevity compounds in mammals — it runs identical protocols simultaneously across three independent research sites (Jackson Laboratory, University of Michigan, University of Texas) using genetically heterogeneous mice, specifically to avoid the single-lab, inbred-strain bias that plagues most longevity research.

Only a small number of compounds have ever shown replicated lifespan extension in the ITP. NDGA is one of them — extending median lifespan in male mice in ITP testing. (Notably, the effect has been less consistent in female mice across trials, a pattern seen with several other ITP compounds and a reminder that sex-specific responses are common in aging research.)

What's Missing#

There is essentially no human trial data on NDGA for longevity. The compound has a history of pharmaceutical interest — it was studied decades ago as a potential cancer therapeutic and antiviral — but that research doesn't translate into knowing whether 50mg/day produces any measurable benefit in a 45-year-old human, let alone whether it's safe over decades of use.

Mechanism#

NDGA is a potent lipoxygenase inhibitor, meaning it blocks an enzyme pathway involved in inflammatory signaling. It also has direct antioxidant activity as a free radical scavenger. Both mechanisms are plausible contributors to the ITP lifespan effect, but neither has been confirmed as the actual cause.

---

Lithium Orotate: The Drinking-Water Hypothesis#

What It Is#

Lithium is a trace mineral, present at very low concentrations in soil and groundwater. At high doses (300–1,800mg/day of lithium carbonate) it's an FDA-approved treatment for bipolar disorder. Lithium orotate is a different salt form, marketed in over-the-counter supplements at doses that deliver a small fraction of the elemental lithium found in psychiatric dosing — often under 5mg of elemental lithium per serving, versus 900mg+ in clinical use.

The Evidence That Matters#

The case for microdose lithium rests on ecological/population studies: research comparing municipalities with naturally higher trace lithium in their drinking water against those with lower levels. Several such studies — across Japan, Texas, and parts of Europe — have found associations between higher water lithium concentration and lower rates of dementia, suicide, and all-cause mortality.

This is genuinely interesting signal. It's also exactly the kind of evidence that should be treated cautiously: ecological studies can't control for the dozens of other variables that differ between regions (diet, healthcare access, socioeconomic factors, other minerals in the water supply). Correlation across populations is a hypothesis-generator, not proof that supplementing isolated lithium in an individual will replicate the effect.

Mechanism#

Lithium's proposed neuroprotective mechanism centers on inhibition of GSK-3β (glycogen synthase kinase 3 beta), an enzyme implicated in tau phosphorylation — a process central to Alzheimer's pathology. Lithium also has documented effects on BDNF (brain-derived neurotrophic factor) expression and may have direct anti-apoptotic effects on neurons. These are credible mechanisms, studied extensively at therapeutic (high) lithium doses — it's far less clear they hold at microdose levels.

The Safety Caveat#

This is the compound that deserves the most caution on this list. Lithium has a genuinely narrow therapeutic index — even therapeutic psychiatric doses require regular blood monitoring because the gap between an effective dose and a toxic one is small. While orotate-form microdosing delivers far less elemental lithium than psychiatric use, "far less" doesn't mean "zero risk," particularly with long-term daily use, kidney function changes with age, or interactions with other medications. Anyone considering this should talk to a physician and get baseline kidney and thyroid function tested first — both organs are affected by chronic lithium exposure even at low doses.

---

Should You Take Either of These?#

NDGA is a reasonable speculative addition for someone already running an extensive evidence-based stack who wants to act on the strongest available animal data, understanding that human translation is unproven.

Lithium orotate carries more individual risk relative to its evidence base. The population data is intriguing, but population data is the weakest tier of evidence in this guide's framework, and lithium's safety profile means the downside of getting it wrong is more serious than missing out on a mouse-study compound.

Neither is something to add reflexively because "Bryan Johnson takes it." His protocol is built around extremely tight biomarker feedback loops — monthly panels, continuous monitoring, a team of physicians reviewing his data — that most people self-experimenting at home don't have. Without that feedback loop, you're taking on the risk side of an experimental compound without the safety net that makes it defensible for him.

See the complete Bryan Johnson Blueprint protocol for the full context these two compounds sit within.